{"pmid":32321720,"title":"Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).","text":["Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).","Ann Rheum Dis","Giollo, Alessandro","Adami, Giovanni","Gatti, Davide","Idolazzi, Luca","Rossini, Maurizio","32321720"],"journal":"Ann Rheum Dis","authors":["Giollo, Alessandro","Adami, Giovanni","Gatti, Davide","Idolazzi, Luca","Rossini, Maurizio"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321720","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217598","keywords":["anti-inflammatory agents, non-steroidal","arthritis, psoriatic","arthritis, rheumatoid","biological therapy","spondylitis, ankylosing"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932650487808,"score":8.518259,"similar":[{"pmid":32241793,"title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.","text":["Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.","Ann Rheum Dis","Monti, Sara","Balduzzi, Silvia","Delvino, Paolo","Bellis, Elisa","Quadrelli, Verdiana Serena","Montecucco, Carlomaurizio","32241793"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Balduzzi, Silvia","Delvino, Paolo","Bellis, Elisa","Quadrelli, Verdiana Serena","Montecucco, Carlomaurizio"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241793","week":"202014|Mar 30 - Apr 05","doi":"10.1136/annrheumdis-2020-217424","keywords":["antirheumatic agents","arthritis, rheumatoid","biological therapy","spondylitis, ankylosing"],"link_comment_in":"32299844","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638249418620929,"score":206.27391},{"pmid":32220865,"title":"Non-steroidal anti-inflammatory drugs and covid-19.","text":["Non-steroidal anti-inflammatory drugs and covid-19.","BMJ","Little, Paul","32220865"],"journal":"BMJ","authors":["Little, Paul"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220865","week":"202014|Mar 30 - Apr 05","doi":"10.1136/bmj.m1185","link_comment_for":"32171076","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638629659541505,"score":162.64835},{"pmid":32321723,"title":"What is the true incidence of COVID-19 in patients with rheumatic diseases?","text":["What is the true incidence of COVID-19 in patients with rheumatic diseases?","Ann Rheum Dis","Favalli, Ennio Giulio","Ingegnoli, Francesca","Cimaz, Rolando","Caporali, Roberto","32321723"],"journal":"Ann Rheum Dis","authors":["Favalli, Ennio Giulio","Ingegnoli, Francesca","Cimaz, Rolando","Caporali, Roberto"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321723","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217615","keywords":["arthritis","biological therapy","hydroxychloroquine"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932732276739,"score":75.09358},{"pmid":32284245,"pmcid":"PMC7151479","title":"The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is \"Safe Better than Sorry\"?","text":["The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is \"Safe Better than Sorry\"?","Eur Urol","Pradere, Benjamin","Ploussard, Guillaume","Catto, James W F","Roupret, Morgan","Misrai, Vincent","32284245"],"journal":"Eur Urol","authors":["Pradere, Benjamin","Ploussard, Guillaume","Catto, James W F","Roupret, Morgan","Misrai, Vincent"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32284245","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.eururo.2020.03.033","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636391693221891,"score":71.629974},{"pmid":32222466,"pmcid":"PMC7102614","title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.","text":["The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.","The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.","Clin Immunol","Zhang, Wen","Zhao, Yan","Zhang, Fengchun","Wang, Qian","Li, Taisheng","Liu, Zhengyin","Wang, Jinglan","Qin, Yan","Zhang, Xuan","Yan, Xiaowei","Zeng, Xiaofeng","Zhang, Shuyang","32222466"],"abstract":["The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system."],"journal":"Clin Immunol","authors":["Zhang, Wen","Zhao, Yan","Zhang, Fengchun","Wang, Qian","Li, Taisheng","Liu, Zhengyin","Wang, Jinglan","Qin, Yan","Zhang, Xuan","Yan, Xiaowei","Zeng, Xiaofeng","Zhang, Shuyang"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222466","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.clim.2020.108393","keywords":["Anti-inflammation treatment","Coronavirus disease 2019 (COVID-19)","Cytokine storm"],"source":"PubMed","locations":["Chinese","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352135193985025,"score":70.33635}]}